<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678080</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-08-0015</org_study_id>
    <nct_id>NCT00678080</nct_id>
  </id_info>
  <brief_title>Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Controlled Trial of Metformin Versus Insulin in Women With Type 2 Diabetes Mellitus During Pregnancy in a Population With Severe Health Disparities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnant women with type 2 diabetes mellitus (T2DM) are at increased risk for miscarriages,
      birth defects, large infants, and stillbirths. Maintaining blood sugars in the normal range
      decreases these pregnancy complications. We hypothesize that metformin will achieve similar
      levels of blood sugar control compared to insulin. In doing so, metformin will prevent the
      increased risk of pregnancy complications associated with T2DM in pregnancy. We propose a
      pilot study of a randomized, controlled trial of metformin versus insulin in the treatment of
      T2DM during pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women with type 2 diabetes mellitus (T2DM) are at increased risk for miscarriages,
      birth defects, large infants, and stillbirths. Maintaining blood sugars in the normal range
      decreases these pregnancy complications. Currently, insulin is the primary medication used to
      treat pregnant women with T2DM. However, it is administered by injection several times a day
      and compliance is low in health disparity populations with high rates of obesity and
      diabetes. Insulin also has the potential to lead to dangerously low blood sugars. Metformin
      is a medication than can be administered as pills and is not associated with dangerous low
      blood sugars. In addition, this insulin sensitizer is the medication of choice for women who
      are obese and have T2DM outside of pregnancy. We hypothesize that metformin will achieve
      similar levels of blood sugar control compared to insulin. In doing so, metformin will
      prevent the increased risk of pregnancy complications associated with T2DM in pregnancy. The
      aims of this study is to determine if in pregnant women with T2DM, metformin achieves similar
      glycemic control, and similar maternal and neonatal outcomes when compared to insulin. We
      propose a pilot study of a randomized, controlled trial of metformin versus insulin in the
      treatment of T2DM during pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Who Achieved a Hemoglobin A1C &lt;7%</measure>
    <time_frame>during third trimester</time_frame>
    <description>The hemoglobin A1c level is an indicator of glycemic control—it indicates the average level of blood sugar over the past 2 to 3 months. Hemoglobin A1c levels 6.5% and higher indicate diabetes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants Who Achieved a Hemoglobin A1C &lt;7%</measure>
    <time_frame>at the time of delivery</time_frame>
    <description>The hemoglobin A1c level is an indicator of glycemic control—it indicates the average level of blood sugar over the past 2 to 3 months. Hemoglobin A1c levels 6.5% and higher indicate diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>at the time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypoglycemia</measure>
    <time_frame>During pregnancy</time_frame>
    <description>Defined as hypoglycemia as documented by neonatal chart based on health care provider description</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Failed Metformin Therapy</measure>
    <time_frame>Duration of pregnancy</time_frame>
    <description>Those whose glucose levels were above target range thereby needing insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had a Cesarean Section</measure>
    <time_frame>At the time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Fetus With Macrosomia</measure>
    <time_frame>At the time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Shoulder Dystocia</measure>
    <time_frame>At the time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had a Newborn With Respiratory Distress Syndrome</measure>
    <time_frame>Neonatal period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Newborns Who Needed Neonatal Dextrose</measure>
    <time_frame>Neonatal period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin therapy as prescribed by their health care provider</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin as prescribed by their health care provider</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin (NPH and Regular)</intervention_name>
    <description>Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The onset of T2DM for less than 10 years prior to the onset of pregnancy by patient
             history

          -  Treatment with diet or oral hypoglycemic agents prior to pregnancy.

          -  Pregnancies less than 20 weeks of pregnancy. This gestational age was chosen to
             include those women who initiated prenatal care in the second trimester, but still
             have the ability to improve their hemoglobin A1C (primary outcome) with medical
             therapy prior to delivery.

          -  Newly diagnosed diabetes in the first 20 weeks of pregnancy. These women likely have
             had diabetes prior to the onset of pregnancy. They do not qualify for the diagnosis of
             gestational diabetes which is typically made after 20 weeks of pregnancy. Diagnosis
             will be made based on an elevated fasting blood glucose greater than 105 mg/dL, a 50
             gram glucola result greater than 200 mg/dL or an abnormal 3 hour glucola test prior to
             20 weeks of pregnancy. An abnormal 3-hour glucola test is defined as 2 out of 4
             abnormal values.

          -  Hemoglobin A1C &lt;9%

        Exclusion Criteria:

          -  Gestational age greater than 20 weeks

          -  Multiple gestations (twins or more gestations)

          -  Type 1 diabetes by patient history

          -  Known fetal chromosomal or structural defects

          -  Contraindications to the use of metformin including renal disease, liver disease,
             prior myocardial infarction or sepsis.

          -  Those with a hemoglobin A1C greater than 9%.

          -  On insulin at the start of pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerrie S Refuerzo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valley Baptist Hospital</name>
      <address>
        <city>Brownsville</city>
        <state>Texas</state>
        <zip>78520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndon B Johnson Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <results_first_submitted>May 26, 2015</results_first_submitted>
  <results_first_submitted_qc>November 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 28, 2018</results_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jerrie Refuerzo</investigator_full_name>
    <investigator_title>Associate Professor - Ob/Gyn Maternal Fetal</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Metformin</keyword>
  <keyword>Insulin</keyword>
  <keyword>Pregnant women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
        </group>
        <group group_id="P2">
          <title>Insulin</title>
          <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
        </group>
        <group group_id="B2">
          <title>Insulin</title>
          <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="5.5"/>
                    <measurement group_id="B2" value="32.3" spread="4.3"/>
                    <measurement group_id="B3" value="31.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Achieved a Hemoglobin A1C &lt;7%</title>
        <description>The hemoglobin A1c level is an indicator of glycemic control—it indicates the average level of blood sugar over the past 2 to 3 months. Hemoglobin A1c levels 6.5% and higher indicate diabetes.</description>
        <time_frame>during third trimester</time_frame>
        <population>During the third trimester, hemoglobin A1c levels were obtained for only 5 in the metformin arm and 12 in the insulin arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Achieved a Hemoglobin A1C &lt;7%</title>
          <description>The hemoglobin A1c level is an indicator of glycemic control—it indicates the average level of blood sugar over the past 2 to 3 months. Hemoglobin A1c levels 6.5% and higher indicate diabetes.</description>
          <population>During the third trimester, hemoglobin A1c levels were obtained for only 5 in the metformin arm and 12 in the insulin arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <time_frame>at the time of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="5.2"/>
                    <measurement group_id="O2" value="40.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypoglycemia</title>
        <description>Defined as hypoglycemia as documented by neonatal chart based on health care provider description</description>
        <time_frame>During pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypoglycemia</title>
          <description>Defined as hypoglycemia as documented by neonatal chart based on health care provider description</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Failed Metformin Therapy</title>
        <description>Those whose glucose levels were above target range thereby needing insulin therapy</description>
        <time_frame>Duration of pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Failed Metformin Therapy</title>
          <description>Those whose glucose levels were above target range thereby needing insulin therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had a Cesarean Section</title>
        <time_frame>At the time of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Cesarean Section</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Fetus With Macrosomia</title>
        <time_frame>At the time of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fetus With Macrosomia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Shoulder Dystocia</title>
        <time_frame>At the time of delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shoulder Dystocia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had a Newborn With Respiratory Distress Syndrome</title>
        <time_frame>Neonatal period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had a Newborn With Respiratory Distress Syndrome</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Newborns Who Needed Neonatal Dextrose</title>
        <time_frame>Neonatal period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Newborns Who Needed Neonatal Dextrose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Achieved a Hemoglobin A1C &lt;7%</title>
        <description>The hemoglobin A1c level is an indicator of glycemic control—it indicates the average level of blood sugar over the past 2 to 3 months. Hemoglobin A1c levels 6.5% and higher indicate diabetes.</description>
        <time_frame>at the time of delivery</time_frame>
        <population>At the time of delivery, hemoglobin A1c levels were obtained for only 5 in the metformin arm and 8 in the insulin arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
          </group>
          <group group_id="O2">
            <title>Insulin</title>
            <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Achieved a Hemoglobin A1C &lt;7%</title>
          <description>The hemoglobin A1c level is an indicator of glycemic control—it indicates the average level of blood sugar over the past 2 to 3 months. Hemoglobin A1c levels 6.5% and higher indicate diabetes.</description>
          <population>At the time of delivery, hemoglobin A1c levels were obtained for only 5 in the metformin arm and 8 in the insulin arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Metformin therapy
Metformin: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily</description>
        </group>
        <group group_id="E2">
          <title>Insulin</title>
          <description>Insulin
Insulin (NPH and Regular): Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jerrie Refuerzo, M.D.</name_or_title>
      <organization>UT Health</organization>
      <phone>713-500-6416</phone>
      <email>jerrie.s.refuerzo@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

